BioAtla (BCAB) Competitors $0.33 -0.03 (-8.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.34 +0.01 (+2.73%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB vs. ELUT, CRVO, PYXS, BYSI, SRZN, FBRX, VNRX, IGMS, IMMX, and CNTXShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Elutia (ELUT), CervoMed (CRVO), Pyxis Oncology (PYXS), BeyondSpring (BYSI), Surrozen (SRZN), Forte Biosciences (FBRX), VolitionRx (VNRX), IGM Biosciences (IGMS), Immix Biopharma (IMMX), and Context Therapeutics (CNTX). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Its Competitors Elutia CervoMed Pyxis Oncology BeyondSpring Surrozen Forte Biosciences VolitionRx IGM Biosciences Immix Biopharma Context Therapeutics Elutia (NASDAQ:ELUT) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership. Do analysts rate ELUT or BCAB? Elutia presently has a consensus price target of $8.00, indicating a potential upside of 292.16%. BioAtla has a consensus price target of $5.00, indicating a potential upside of 1,415.15%. Given BioAtla's higher probable upside, analysts plainly believe BioAtla is more favorable than Elutia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media favor ELUT or BCAB? In the previous week, Elutia had 3 more articles in the media than BioAtla. MarketBeat recorded 4 mentions for Elutia and 1 mentions for BioAtla. BioAtla's average media sentiment score of 0.92 beat Elutia's score of 0.44 indicating that BioAtla is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elutia 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioAtla 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ELUT or BCAB? Elutia has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Which has stronger valuation & earnings, ELUT or BCAB? Elutia has higher revenue and earnings than BioAtla. Elutia is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElutia$24.38M3.44-$53.95M-$1.93-1.06BioAtla$11M1.75-$69.78M-$1.22-0.27 Is ELUT or BCAB more profitable? BioAtla has a net margin of 0.00% compared to Elutia's net margin of -168.23%. Elutia's return on equity of 0.00% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets Elutia-168.23% N/A -96.70% BioAtla N/A -373.47%-116.55% Do institutionals & insiders believe in ELUT or BCAB? 74.0% of Elutia shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 27.6% of Elutia shares are owned by company insiders. Comparatively, 11.5% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryElutia beats BioAtla on 9 of the 16 factors compared between the two stocks. Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.98M$2.99B$5.48B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-0.2717.7428.8623.83Price / Sales1.75178.75371.7266.14Price / CashN/A41.9535.4557.96Price / Book1.328.508.275.54Net Income-$69.78M-$55.06M$3.25B$259.28M7 Day Performance-6.99%-3.99%-3.73%-4.68%1 Month Performance-17.02%9.58%4.29%4.36%1 Year Performance-79.25%6.70%25.87%17.89% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla2.0646 of 5 stars$0.33-8.1%$5.00+1,415.2%-81.1%$20.98M$11M-0.2760Upcoming EarningsELUTElutia3.452 of 5 stars$1.97+2.6%$8.00+306.1%-40.4%$78.94M$24.38M-1.02180News CoverageUpcoming EarningsGap DownCRVOCervoMed2.6636 of 5 stars$8.67-3.5%$20.50+136.4%-28.6%$78.15M$9.74M-3.984Upcoming EarningsAnalyst ForecastGap DownHigh Trading VolumePYXSPyxis Oncology1.6893 of 5 stars$1.23-2.0%$9.00+634.7%-70.2%$77.43M$16.15M-0.7760BYSIBeyondSpringN/A$1.92flatN/A+6.7%$77.41M$1.75M0.0080SRZNSurrozen1.8365 of 5 stars$9.31+4.0%$38.50+313.5%+36.1%$76.64M$10.65M-0.3780Gap DownFBRXForte Biosciences3.1131 of 5 stars$11.63+0.3%$61.00+424.5%+43,661.4%$76.37MN/A-0.715Positive NewsVNRXVolitionRx1.4714 of 5 stars$0.73-2.6%$3.50+379.3%-3.5%$75.94M$1.31M-2.0380Gap UpIGMSIGM Biosciences4.2687 of 5 stars$1.26-0.8%$5.50+336.5%-86.5%$75.91M$2.68M-0.39190News CoveragePositive NewsEarnings ReportHigh Trading VolumeIMMXImmix Biopharma2.6353 of 5 stars$2.72+0.4%$7.00+157.4%+27.4%$75.55MN/A-3.899News CoveragePositive NewsCNTXContext Therapeutics2.5921 of 5 stars$0.85+1.1%$5.50+547.1%-68.2%$75.44MN/A-2.747News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies ELUT Alternatives CRVO Alternatives PYXS Alternatives BYSI Alternatives SRZN Alternatives FBRX Alternatives VNRX Alternatives IGMS Alternatives IMMX Alternatives CNTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
